of CBT or an SSRI or SNRI for longer periods is associated with an increase in overall response and helps to prevent relapse .
There is a need for improvement in the treatment of GAD because the ideal anxiolytic drug does not exist, while CBT is not universally available especially in primary care where the majority of GAD patients fi rst present. In this issue, two views from either side of the Atlantic are presented on the potential role of pregabalin in the treatment of GAD (Baldwin and Ajel 2007; Strawn and Geracioti 2007) . Pregabalin is already approved in many countries for the treatment of chronic neuropathic pain and some forms of epilepsy. Its mechanism of action differs from that of known past treatments for GAD -although structurally related to GABA, pregabalin neither binds to benzodiazepine, GABA A or GABA B receptors, nor affects GABA currents in the brain. It seems to bind to the α 2 δ sub-unit of brain voltage-gated N-type calcium channels, thereby decreasing presynaptic calcium currents and consequently lowering the release of a number of neurotransmitters which have been shown to be involved in the pathophysiology of GAD such as glutamate, substance P, and noradrenaline.
The effi cacy of pregabalin in the acute treatment of GAD and prevention of relapse is well established in a series of randomized, placebo-controlled trials. When compared with existing treatments, it may offer an earlier onset of action than venlafaxine and better effi cacy across the range of psychological and somatic symptoms of anxiety than alprazolam or lorazepam. No specifi c antidepressant effects have yet been demonstrated and there is no study comparing pregabalin with either CBT or a SSRI in GAD, which is problematical since most GAD patients in clinical settings have signifi cant co-existing depressive symptoms. The major side effects are dizziness and somnolence, while weight gain may be a problem, but in acute treatment studies pregabalin was generally better tolerated than benzodiazepines and venlafaxine. All-in-all, pregabalin is a promising newcomer for the treatment of GAD which may ultimately prove to be a viable alternative to current therapies. However, more (clinical) research is needed!
